From bench to clinical trials: the rFIXFc story

BrandeisNOW has a new story about the development of recombinant Factor IX Fc,¬† a candidate drug for hemophila, currently in Phase III cliniical trials. The story behind the Fc fusion technology started in academic labs including Neil Simister‘s at Brandeis, led to a biotech startup (Syntonix), which was then acquired by Biogen Idec, who are now conducing clinical trials.

For more, see http://www.brandeis.edu/now/2011/june/hemophilia.html

Protected by Akismet
Blog with WordPress

Welcome Guest | Login (Brandeis Members Only)